- Home
- KFY vs KNSA Comparison
KFY vs KNSA Comparison
Compare KFY & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KFY | KNSA |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KFY | KNSA |
|---|---|---|
| Price | $63.04 | $46.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $73.00 | $55.29 |
| AVG Volume (30 Days) | 485.9K | ★ 534.9K |
| Earning Date | 03-09-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | 42.41 | ★ 225.00 |
| EPS | ★ 3.84 | 0.75 |
| Revenue | ★ $1,819,519,000.00 | $677,564,000.00 |
| Revenue This Year | $6.92 | $38.01 |
| Revenue Next Year | $3.25 | $17.42 |
| P/E Ratio | ★ $15.74 | $62.71 |
| Revenue Growth | 12.20 | ★ 60.09 |
| 52 Week Low | $58.27 | $19.62 |
| 52 Week High | $78.50 | $50.03 |
Technical Indicators
Market Signals| Indicator | KFY | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 49.84 |
| Support Level | $61.98 | $39.96 |
| Resistance Level | $64.96 | $48.61 |
| Average True Range (ATR) | 1.93 | 1.85 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 52.31 | 40.34 |
Price Performance
Historical ComparisonAbout KFY Korn Ferry
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.